Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1986-2-24
|
| pubmed:abstractText |
Fluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p less than 0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-8967
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
85
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
636-43
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:3937441-Adult,
pubmed-meshheading:3937441-Ambulatory Care,
pubmed-meshheading:3937441-Antidepressive Agents,
pubmed-meshheading:3937441-Depressive Disorder,
pubmed-meshheading:3937441-Female,
pubmed-meshheading:3937441-Fluvoxamine,
pubmed-meshheading:3937441-Humans,
pubmed-meshheading:3937441-Male,
pubmed-meshheading:3937441-Oximes,
pubmed-meshheading:3937441-Psychiatric Status Rating Scales
|
| pubmed:articleTitle |
A Belgian multicentre study of fluvoxamine in depressive outpatients.
|
| pubmed:publicationType |
Journal Article
|